Form 4 for SION Sionna Therapeutics, Inc.
Accepted 2025-02-10 00:00:00 ET · period of report 2025-02-10 · accession 0000950170-25-017030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-02-10 | 2025-02-10 | SION | Atlas Venture Fund XI, L.P. | 10% | P - Purchase | $18.00 | +60.0K | 807.7K | +8% | +$1.08M |
| DI | 2025-02-10 | 2025-02-10 | SION | Atlas Venture Fund XI, L.P. | 10% | C - Cnv Deriv | — | +747.7K | 747.7K | New | — |
| D | 2025-02-10 | 2025-02-10 | SION | Atlas Venture Fund XI, L.P. | 10% | C - Cnv Deriv | — | +2.89M | 2.89M | New | — |
| DM | 2025-02-10 | 2025-02-10 | SION | Atlas Venture Fund XI, L.P. | 10% | C - Cnv Deriv | $0.00 | -4.22M | 0 | -100% | $0 |
| DI | 2025-02-10 | 2025-02-10 | SION | Atlas Venture Fund XI, L.P. | 10% | C - Cnv Deriv | $0.00 | -1.09M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | P | A | 60,000 | $18.00 | 807,727 | I | — | — | |
| 2 | Common | Common Stock | 2025-02-10 | C | A | 747,727 | — | 747,727 | I By Atlas Venture Opportunity Fund II, L.P. | — | — | (F1) Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. (F3) These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| 3 | Common | Common Stock | 2025-02-10 | C | A | 2,886,293 | — | 2,886,293 | D By Atlas Venture Opportunity Fund II, L.P. | — | — | (F1) Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. (F2) These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. (F3) These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| 4 | Derivative | Series A convertible preferred stock | 2025-02-10 | C | D | 1,806,317 | $0.00 | 0 | D | — · — to — | 1,236,271 Common Stock | (F2) These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. (F1) Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. |
| 5 | Derivative | Series C convertible preferred stock | 2025-02-10 | C | D | 61,463 | $0.00 | 0 | D | — · — to — | 42,068 Common Stock | (F2) These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. (F1) Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. |
| 6 | Derivative | Series C convertible preferred stock | 2025-02-10 | C | D | 1,092,504 | $0.00 | 0 | I | — · — to — | 747,727 Common Stock | (F1) Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. |
| 7 | Derivative | Series Seed convertible preferred stock | 2025-02-10 | C | D | 1,051,051 | $0.00 | 0 | D By Atlas Venture Opportunity Fund II, L.P. | — · — to — | 719,355 Common Stock | (F2) These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. (F3) These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. (F1) Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. |
| 8 | Derivative | Series B convertible preferred stock | 2025-02-10 | C | D | 1,298,332 | $0.00 | 0 | D | — · — to — | 888,599 Common Stock | (F2) These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. (F1) Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. |